Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Japan-Based Shinogi's COVID-19 Drug Associated With Birth Defects: Bloomberg

  • Shionogi & Co stock slumped 16% in Tokyo after preclinical studies showed its experimental COVID-19 drug disturbed fetal development, triggering concerns about its approval
  • Kyodo News reported that the drug likely wouldn’t be recommended for pregnant women without giving attribution. 
  • The animal data, which showed harm when given at high doses, was submitted to Japanese regulators in February when the company sought a priority review required for conditional approval, a Shionogi spokesman said. 
  • The pill’s chance of commercial success fell to 5% from 50% after the report tying it to birth defects, making it less competitive, said Stephen Baker, an equities analyst at Jefferies & Co. 
  • He cut his rating on the stock to “underperform” from “buy”, after trimming the profit estimates and target price.
  • “The Japanese will probably approve it but probably on strict conditions,” Barker said. “I think it will impact the company’s ability to conclude a licensing deal with a third party because I don’t think it will be a major commercial success.”
  • Merck & Co Inc’s (NYSE: MRK) Lagevrio (molnupiravir) has a boxed warning saying pregnant women shouldn’t take it after it was linked to fetal harm in animal studies. 
  • Pfizer Inc’s (NYSE: PFE) Paxlovid at high doses led to a decrease in fetal body weight in a rabbit study, though there aren’t restrictions on its use during pregnancy.
  • Photo by Thomas Breher from Pixabay
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.